MiMedx Group, Inc. ( MDXG ) NASDAQ Capital Market

Cena: 5.92 ( 1.81% )

Aktualizacja 06-23 21:17
NASDAQ Capital Market
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 895
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 71%
Ilość akcji: 116 377 000
Debiut giełdowy: 2008-02-12
WWW: https://www.mimedx.com
CEO: Mr. Joseph H. Capper
Adres: 1775 West Oak Commons Court, NE
Siedziba: 30062 Marietta
ISIN: US6024961012
Opis firmy:

Mimedx Group, Inc. opracowuje i rozpowszechnia przeszczepy tkanek łożyska dla różnych sektorów opieki zdrowotnej. Przetwarza ludzkie tkanki łożyska wykorzystujące opatentowany i zastrzeżony proces purecji do wytwarzania przeszczepów, które zachowują nieodłączne właściwości biologiczne i białka regulacyjne. Opatentowana i zastrzeżona metoda przetwarzania firmy stosuje aseptyczne techniki przetwarzania oprócz sterylizacji końcowej. Jego produkty obejmują Epifix, półprzewodnikowy produkt membrany barierowej stosowany w leczeniu ran przewlekłych, w tym owrzodzeń stóp cukrzycowych, owrzodzeń nóg żylnych i owrzodzeń ciśnienia; Amniofix, półprzepuszczalny przeszczep bariery ochronnej, który zawiera odwodnioną błonę płodową/ochronę ludzkiego do stosowania w zastosowaniach chirurgicznych; OPIKORD I AMNIOCORD to odwodnione ludzkie przeszczepy pępowinowe, które są wykorzystywane do zapewnienia środowiska ochronnego do procesu gojenia, a także stosowane w zaawansowanej pielęgnacji ran i zastosowaniach chirurgicznych; a amnioburn Półprzewodnikowy przeszczep barierowy stosowany w leczeniu częściowej grubości i oparzeń z pełną grubością, a także produkt ołowiowy obejmuje MDHACM, mikronizowaną formę amniofix, dostarczaną w postaci proszku. Produkty firmy mają zastosowania przede wszystkim w zakresie opieki ran, oparzenia, chirurgicznego i nieoperacyjnego sektora medycyny sportowej. Sprzedaje również przeszczepy do zastosowań dentystycznych na zasadzie producenta oryginalnego sprzętu. Firma sprzedaje swoje produkty za pośrednictwem bezpośrednich sił sprzedaży i niezależnych agentów sprzedaży, a także za pośrednictwem niezależnych dystrybutorów przede wszystkim w Stanach Zjednoczonych. Mimedx Group, Inc. ma siedzibę w Marietcie w stanie Georgia.

Wskaźniki finansowe
Kapitalizacja (USD) 873 657 330
Aktywa: 243 891 000
Cena: 5.92
Wskaźnik Altman Z-Score: 15.9
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 21.9
Ilość akcji w obrocie: 71%
Średni wolumen: 660 650
Ilość akcji 147 702 000
Wskaźniki finansowe
Przychody TTM 342 805 000
Zobowiązania: 62 883 000
Przedział 52 tyg.: 5.47 - 10.14
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: 0.3
P/E branży: 26.1
Beta: 1.939
Raport okresowy: 2025-07-29
WWW: https://www.mimedx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. William F. Hulse IV General Counsel & Chief Administrative Officer 959 591 1974
Dr. Robert Benjamin Stein M.D., Ph.D. President of Regenerative Medicine & Biologics Innovation 639 284 1951
Mr. Scott M. Turner Senior Vice President of Operations & Procurement 493 975 1966
Mr. Douglas C. Rice CPA Chief Financial Officer 470 467 1966
Mr. Joseph H. Capper Chief Executive Officer & Director 1 546 346 1964
Ms. Kate Surdez Chief Human Resources Officer 0 0
Mr. Mark P. Graves Senior Vice President & Chief Compliance Officer 0 1966
Dr. David H. Mason Jr. Chief Medical Officer 0 1947
Hilary Dixon Vice President of Investor Relations & Corporate Strategic Communications 0 0
Mr. Matthew M. Notarianni Head of Investor Relations 0 0
Wiadomości dla MiMedx Group, Inc.
Tytuł Treść Źródło Aktualizacja Link
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV. globenewswire.com 2025-05-06 12:00:00 Czytaj oryginał (ang.)
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS) Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product globenewswire.com 2025-05-05 12:30:00 Czytaj oryginał (ang.)
MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Matthew Notarianni - Head, IR Joseph Capper - CEO & Director Doug Rice - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Anthony Petrone - Mizuho Group Operator Good afternoon, and thank you for standing by. Welcome to the MIMEDX First Quarter 2025 Operating and Financial Results Conference Call. seekingalpha.com 2025-05-01 01:52:10 Czytaj oryginał (ang.)
MiMedx (MDXG) Q1 Earnings Match Estimates MiMedx (MDXG) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago. zacks.com 2025-04-30 22:15:31 Czytaj oryginał (ang.)
MIMEDX Announces First Quarter 2025 Operating and Financial Results Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025 , at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2025. globenewswire.com 2025-04-30 20:01:00 Czytaj oryginał (ang.)
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. globenewswire.com 2025-04-10 20:01:00 Czytaj oryginał (ang.)
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference. globenewswire.com 2025-02-27 10:00:00 Czytaj oryginał (ang.)
MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript MiMedx Group, Inc. (NASDAQ:MDXG ) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Bradley Bowers - Mizuho Securities Brooks O'Neil - Lake Street Capital Markets Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2024 Operating Financial Results Conference Call. seekingalpha.com 2025-02-27 00:50:46 Czytaj oryginał (ang.)
MiMedx (MDXG) Q4 Earnings Meet Estimates MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago. zacks.com 2025-02-26 20:55:24 Czytaj oryginał (ang.)
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹  was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2024. globenewswire.com 2025-02-26 18:01:00 Czytaj oryginał (ang.)
MiMedx (MDXG) is on the Move, Here's Why the Trend Could be Sustainable MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com 2024-12-18 11:50:28 Czytaj oryginał (ang.)
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, MiMedx (MDXG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. zacks.com 2024-12-02 16:25:34 Czytaj oryginał (ang.)
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why MiMedx (MDXG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com 2024-12-02 16:25:26 Czytaj oryginał (ang.)
How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12% The mean of analysts' price targets for MiMedx (MDXG) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com 2024-11-20 12:55:23 Czytaj oryginał (ang.)
MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com 2024-11-15 11:50:19 Czytaj oryginał (ang.)
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. globenewswire.com 2024-11-14 11:15:00 Czytaj oryginał (ang.)
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect? The consensus price target hints at a 77.9% upside potential for MiMedx (MDXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-11-04 12:55:25 Czytaj oryginał (ang.)
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Brad Bowers - Mizuho Securities Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter 2024 Operating and Financial Results Conference Call. seekingalpha.com 2024-10-30 23:38:06 Czytaj oryginał (ang.)
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago. zacks.com 2024-10-30 20:26:12 Czytaj oryginał (ang.)
MIMEDX Announces Third Quarter 2024 Operating and Financial Results Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05 , Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET globenewswire.com 2024-10-30 18:01:00 Czytaj oryginał (ang.)
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30 MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. globenewswire.com 2024-10-14 12:00:00 Czytaj oryginał (ang.)
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today's New York Times: “Her Face Was Unrecognizable After an Explosion. globenewswire.com 2024-10-08 20:01:00 Czytaj oryginał (ang.)
MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research   MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. globenewswire.com 2024-10-01 20:01:00 Czytaj oryginał (ang.)
EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS" 10 Former MiMedx Employees In Non-Compete Suit Fight Back Against MiMedx Schemes to "Bilk Medicare" and "Incentivize Fraud" in Counterclaims Filed by Mintz Attorneys MARIETTA, Ga. , Sept. 11, 2024 /PRNewswire/ -- 10 former employees of MiMedx Group, Inc. (NASDAQ: MDXG) have now filed counterclaims against the placental biologics company in response to a non-compete lawsuit filed by MiMedx earlier this year. prnewswire.com 2024-09-11 17:03:00 Czytaj oryginał (ang.)
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES' Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga. , Sept. 4, 2024 /PRNewswire/ -- The third of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the company. prnewswire.com 2024-09-04 20:23:00 Czytaj oryginał (ang.)
DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga. , Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the placental biologics company. prnewswire.com 2024-08-26 13:30:00 Czytaj oryginał (ang.)
MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Chase Knickerbocker - Craig-Hallum Capital Group Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Operator Greetings and welcome to the MiMedx Second Quarter 2024 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-08-01 01:10:26 Czytaj oryginał (ang.)
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products globenewswire.com 2024-07-31 20:02:00 Czytaj oryginał (ang.)
MIMEDX Announces Second Quarter 2024 Operating and Financial Results Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12 , Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024 , at 4:30 PM ET MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2024. globenewswire.com 2024-07-31 20:01:00 Czytaj oryginał (ang.)
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process globenewswire.com 2024-07-22 12:10:00 Czytaj oryginał (ang.)